Alumis Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 6.73 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 871.10M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Details
| Name | Alumis Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 239 |
| Founded | 2021 |
| Ipo Date | 2024-06-28 |
| Ceo | Martin Babler |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US0223071020 |
| Cusip | 022307102 |
| Cik | 1847367 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Martin Babler Ph.D. | President, Chief Executive Officer and Chairman |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer and Head of Research and Development |
| John R. Schroer C.F.A. | Chief Financial Officer |
| Sanam Pangali J.D. | Chief Legal Officer and Corporate Secretary |
| Roy C. Hardiman J.D. | Chief Business and Strategy Officer |
| Claire Langrish Ph.D. | Senior Vice President and Head of Immunology and Translational Science |
| Philip Nunn Ph.D. | Senior Vice President of Pharmacology and Project Team Leader |
| Mark Bradley | Chief Development Officer |
| Kolbot By Ph.D. | Senior Vice President and Head of Technical Operations |
Contact
| Address | 280 East Grand Avenue, South San Francisco, California 94080, United States |
| Phone | 650 231 6625 |
| Website | https://www.alumis.com |